On September 29, 2025, President Donald J. Trump issued a proclamation imposing new tariffs on imports of timber, lumber, and wood products as a result of an ongoing investigation under Section 232 of the Trade Expansion Act of 1962 that was initiated on March 1, 2025. In accordance with this investigation, the President concluded that duties should be imposed on certain timber, lumber, and wood products to address national security concerns. To address these concerns,…
On September 25, President Donald Trump took to his social media platform Truth Social to announce a new wave of tariffs under Section 232 of the Trade Expansion Act, targeting furniture, pharmaceuticals and trucks. These measures, set to take effect on October 1, 2025, are framed as necessary for national security and are being implemented to revitalize domestic manufacturing, and seem to follow from the previously announced initiation of Section 232 investigations covering such products.…
Effective today, August 29, 2025, de minimis duty-free treatment under 19 U.S.C. § 1321(a)(2)(C) is no longer available for shipments valued at $800 or less, entering into the United States, including those entering through international mail, under Executive Order (“EO”) 14324 of July 30, 2025. Carriers delivering shipments to the United States through the international postal network, or other qualifying parties that are approved by Customs and Border Protection (“CBP”), must collect and remit duties to CBP…
On August 25, U.S. Customs and Border Protection (“CBP”) issued a draft Federal Register notice to effectuate the President’s Executive Order (“EO”) on “Addressing Threats to the United States by the Government of the Russian Federation,” which imposed additional tariffs on imports of Indian origin due to India directly or indirectly importing Russian oil. Under these new tariffs, imports of most goods of Indian origin will be subject to an additional 25% duty, effective August 27, which…
On July 7, President Trump announced revised tariffs rates for certain trading partners that will take effect on August 1 and extended the postponement of his “Liberation Day” tariffs. The revised tariffs were announced via letters to 14 countries and range from 25% to 40%. These actions come mere days before President Trump’s reciprocal tariffs, which were paused to allow for the negotiation of bilateral trade agreements, were due to resume on July 9 for…
On June 17, the plaintiff-appellees in Learning Resources, Inc., et al v. Donald Trump, et al petitioned the Supreme Court of the United States for certiorari, asking the Court to consider the lawfulness of tariffs President Trump imposed under the putative authority of the International Emergency Economic Powers Act (IEEPA). With the appeal currently pending before the Court of Appeals for the District of Columbia Circuit (D.C. Circuit), the petition takes the uncommon step of…
On June 3, President Trump signed a proclamation increasing tariffs on certain imported steel and aluminum to 50% under Section 232 of the Trade Expansion Act of 1962. The proclamation increases the applicable rate of these duties from 25% and makes additional changes as to the applicable duties for certain products which could be subject to multiple tariff schemes. A summary of the effects of this June 3 proclamation are outlined in this update. Key…
Following a busy week in trade, with numerous US court decisions over the past days, businesses may be left wondering as the week wraps up: where does the recent flurry of decisions leave us? Where things stand Refresher on how we got here
In a landmark decision, the United States Court of International Trade (“CIT”) has ruled against the President’s imposition of tariffs under the International Emergency Economic Powers Act (“IEEPA”). The decision (involving two consolidated cases, V.O.S. Selections, Inc. et al. v. United States of America et al. and The State of Oregon et al. v. United States Department of Homeland Security et al.), is the first court decision on the Administration’s trade policy and the first…
In briefThe US Department of Commerce (“Commerce”) has initiated a Section 232 national security investigation into the imports of pharmaceuticals and pharmaceutical ingredients. This investigation aims to determine whether these imports threaten US national security. The scope of the investigation includes finished drug products, medical countermeasures, critical inputs such as active pharmaceutical ingredients (APIs), key starting materials, and derivative products of these items. Commerce may restrict imports of these products through tariffs, quotas, or other…